Search

Your search keyword '"Thiebaut R"' showing total 61 results

Search Constraints

Start Over You searched for: Author "Thiebaut R" Remove constraint Author: "Thiebaut R" Database OpenAIRE Remove constraint Database: OpenAIRE
61 results on '"Thiebaut R"'

Search Results

1. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy

2. No need for secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/µL

3. Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa

4. Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus co-infected HIV patients with cirrhosis

5. Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response:a sub-study of the NEAT001/ANRS143 randomized trial

6. No need for secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/µL

7. Long‐term effectiveness of recommended boosted protease inhibitor‐based antiretroviral therapy in Europe

8. Global temporal changes in the proportion of children with advanced disease at the start of combination antiretroviral therapy in an era of changing criteria for treatment initiation

9. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens

10. Temporal trends of population viral suppression in the context of Universal Test and Treat : the ANRS 12249 TasP trial in rural South Africa

11. Effect of incident hepatitis C infection on CD4(+) cell count and HIV RNA trajectories based on a multinational HIV seroconversion cohort

12. Determinants of Restoration of CD4 and CD8 Cell Counts and Their Ratio in HIV-1-Positive Individuals With Sustained Virological Suppression on Antiretroviral Therapy

13. Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study

14. Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients

15. Associations between HIV-RNA-based indicators and virological and clinical outcomes

16. Mortality in migrants living with HIV in western Europe (1997–2013): a collaborative cohort study

17. Microbial translocation does not drive immune activation in Ugandan children with HIV

18. Predictors of CD4 cell recovery following initiation of antiretroviral therapy among HIV-1 positive patients with well-estimated dates of seroconversion

19. Universal test and treat and the HIV epidemic in rural South Africa : a phase 4, open-label, community cluster randomised trial

20. Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIRaben-1 subtype B and non-subtype B receiving a salvage regimen

21. Chronic hepatitis B and C virus infection and risk for non-hodgkin lymphoma in HIV-infected patients: A cohort study

22. CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: A multinational, multicohort European study

23. Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naive patients

25. Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes

26. Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression : A prospective cohort study

28. Infection-related and -unrelated malignancies, HIV and the aging population

29. Associations between HIV-RNA-based indicators and virological and clinical outcomes

30. Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIRaben-1 subtype B and non-subtype B receiving a salvage regimen

31. Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy

32. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study

33. Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4 + T-cell recovery once HIV-1 suppression is achieved?

34. Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4 + T-cell recovery once HIV-1 suppression is achieved?

35. Combination antiretroviral therapy and the risk of myocardial infarction

36. Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery

37. An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration

39. TB Meningitis in HIV-Positive Patients in Europe and Argentina: Clinical Outcome and Factors Associated with Mortality

40. Impact of HIV-1 subtype on CD4 count at HIV seroconversion, rate of decline, and viral load set point in European seroconverter cohorts

41. The incidence of AIDS-defining illnesses at a current CD4 count ≥200 cells/μL in the post-combination antiretroviral therapy era

42. CD4 cell count and the risk of AIDS or death in HIV-Infected adults oncombination antiretroviral therapy with a suppressed viral load: a longitudinalcohort study from COHERE

43. Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe

44. Risk of triple-class virological failure in children with HIV: a retrospective cohort study

45. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis

46. Inference in HIV dynamics models via hierarchical likelihood

48. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era

49. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study

50. Combination antiretroviral therapy and the risk of myocardial infarction

Catalog

Books, media, physical & digital resources